CliffBio
small molecule

CAPRELSA

VANDETANIB

Loss of exclusivityAugust 2028latest FDA-listed patent expiry
CompanyGenzyme →See this company's full patent-cliff portfolio

Drug detail

Brand nameCAPRELSA
Active ingredientVANDETANIB
Strength300MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2011
Marketing statusRX

Listed patents

PatentExpiresType
8067427August 2028product

More from Genzyme

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

CAPRELSA patent cliff — loss of exclusivity August 2028 | CliffBio